Lebrikizumab Phase 3 Nummular Eczema Trial, Apr 21
Summary
NIH ClinicalTrials.gov registered Phase 3 trial NCT07542483 evaluating lebrikizumab in adults with Nummular Eczema inadequately controlled with topical corticosteroids. The randomized, placebo-controlled study will assess efficacy, safety, and tolerability of lebrikizumab monotherapy.
About this source
GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 578 changes logged to date.
What changed
NIH ClinicalTrials.gov registered a new Phase 3 clinical trial (NCT07542483) for lebrikizumab in adult participants with Nummular Eczema who are not adequately controlled with topical corticosteroids or when that treatment is not medically advisable. The randomized, double-blind study will evaluate lebrikizumab monotherapy against placebo.
Pharmaceutical companies, clinical investigators, and healthcare providers involved in dermatology research should note this trial's scope and inclusion criteria when designing competing or complementary studies in the Nummular Eczema indication.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Study of Lebrikizumab in Adults With Nummular Eczema
Phase 3 NCT07542483 Kind: PHASE3 Apr 21, 2026
Abstract
The main aim of the study is to evaluate the efficacy, safety, and tolerability of lebrikizumab treatment in adult participants with Nummular Eczema (NE) who are not adequately controlled with Topical corticosteroids (TCS) or when this treatment is not medically advisable.
Conditions: Nummular Eczema
Interventions: Lebrikizumab, Placebo
Mentioned entities
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.